STOCK TITAN

DarioHealth Announces Agreement with Global Employer for Metabolic and Musculoskeletal Health Solutions

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Very Positive)
Tags

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today an agreement with a global company based in the United States ("Company") to provide its integrated digital health management solution for diabetes, hypertension, and musculoskeletal (MSK) health. The contract is expected to launch in the first quarter of 2022.

DarioHealth logo

Significant overlap exists between metabolic conditions like diabetes and musculoskeletal health; more than a third of people living with diabetes also experience musculoskeletal pain.1 The Company selected Dario to provide a highly personalized approach to chronic condition management to help improve employee health and reduce the cost of care. Dario's digital therapeutic platform integrates digital tools, medical devices, and digital and human coaching across one experience, delivering a seamless user journey for employees to help them change their behavior to better manage their chronic conditions.

"We are pleased to add another self-insured employer as a customer bringing our total additions in the second quarter to 7. As a multi-condition agreement, we believe this validates our strategy of building a multi-condition platform and demonstrates the speed with which we have been able to incorporate these new conditions into our product offering.  We look forward to working with the Company to help their employees improve their chronic conditions," said Rick Anderson, President and General Manager of North American at DarioHealth.

1 [A. Majjad, Y. Errahali, H. Toufik, J. H Djossou, M. A. Ghassem, J. Kasouati, A. El Maghraoui, "Musculoskeletal Disorders in Patients with Diabetes Mellitus: A Cross-Sectional Study", International Journal of Rheumatology, vol. 2018, Article ID 3839872, 6 pages, 2018. https://doi.org/10.1155/2018/3839872]

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market - covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.

Dario's next-generation, AI-powered, digital therapeutic platform supports more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes.

Dario's unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.

The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users' health.

On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected timing of the contract launch, the belief that the contract validates its strategy of building a multi-condition platform and demonstrates the speed with which it has been able to incorporate these new conditions into its product offering, the belief that the contract signals increasing demand in the employer market for an integrated, chronic condition management solution, and the potential benefits that may be realized by users utilizing the Dario platform. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact

Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220

Media Contact:

Josephine Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262

Logo - http://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

 

Cision View original content:https://www.prnewswire.com/news-releases/dariohealth-announces-agreement-with-global-employer-for-metabolic-and-musculoskeletal-health-solutions-301395021.html

SOURCE DarioHealth Corp.

DarioHealth Corp.

NASDAQ:DRIO

DRIO Rankings

DRIO Latest News

DRIO Stock Data

24.68M
34.10M
17.7%
23.54%
5.88%
Health Information Services
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK